tiprankstipranks
Avacta Group PLC (GB:AVCT)
LSE:AVCT
UK Market
AVCT
Avacta Group plc
RESEARCH TOOLSreports
Want to see GB:AVCT full AI Analyst Report?

Avacta Group plc (AVCT) Earnings Dates, Call Summary & Reports

79 Followers

Earnings Data

Report Date
Oct 05, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
―
Last Year’s EPS
-0.04
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:May 19, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.
Company Guidance
The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Encouraging AVA6000 Clinical Progress and Regulatory Outcome
AVA6000 (Gen One) reported preliminary efficacy and safety in salivary gland cancer; Phase Ib continues with a recommended dose for expansion (RDE) defined at 310 mg/m2; favorable cardiac safety data resulted in lifting of the lifetime maximum doxorubicin dose constraint.
Strong Preclinical Differentiation vs ADCs
Preclinical translational data show up to ~40x higher tumor Cmax for released exatecan (AVA6103) versus comparator ADC payloads and ~3x higher tumor selectivity index (tumor vs plasma) — key mechanistic advantages that may translate clinically.
Increased R&D Investment Reflecting Pipeline Focus
Research & development spend rose to GBP 18.8m in FY2025 from GBP 14.3m prior year, a ~31.5% increase, reflecting focused investment in the proprietary pre|CISION peptide drug conjugate platform and therapeutic programs.
Improved Cost Efficiency in Administration and Cash Outflows
Administrative expenses fell to ~GBP 10m from GBP 12m (~16.7% reduction). Net operating cash outflows improved to GBP 22.64m from GBP 24.94m (~9.2% reduction year-on-year).
Fundraising and Cash Position
Raised GBP 32.5m over the last 18 months (including an oversubscribed placing/subscription of GBP 10m); cash at end-April 2026 was GBP 16.4m, extending runway into early Q1 2027 (projection excludes partnering income).
Pipeline & IP Expansion — Gen Two and Gen Three Progress
Updated in vivo data for Gen Two (AVA6103) and Gen Three (AVA6207 dual-payload) at AACR; continued growth of IP estate protecting sustained release and dual-payload technologies; dual-payload capability is a novel differentiator.

Avacta Group plc (GB:AVCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

GB:AVCT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 05, 2026
2026 (Q2)
- / -
-0.042―――
May 19, 2026
2025 (Q4)
- / -0.05
――――
Sep 30, 2025
2025 (Q2)
- / -0.04
-0.038-10.53% (>-0.01)――
Jun 06, 2025
2024 (Q4)
- / -
-0.049―――
Sep 30, 2024
2024 (Q2)
- / -0.04
-0.04311.63% (<+0.01)――
Apr 30, 2024
2023 (Q4)
- / -0.05
-0.11657.76% (+0.07)――
Sep 28, 2023
2023 (Q2)
- / -0.04
-0.036-19.44% (>-0.01)――
Apr 25, 2023
2022 (Q4)
-0.05 / -0.12
-0.064-81.25% (-0.05)――
Sep 29, 2022
2022 (Q2)
- / -0.04
-0.04112.20% (<+0.01)――
Apr 06, 2022
2021 (Q4)
- / -0.06
-0.048-33.33% (-0.02)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:AVCT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 19, 2026
84.50 p82.00 p-2.96%
Sep 30, 2025
51.00 p59.50 p+16.67%
Jun 06, 2025
34.25 p32.50 p-5.11%
Sep 30, 2024
51.50 p49.00 p-4.85%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Avacta Group PLC (GB:AVCT) report earnings?
Avacta Group PLC (GB:AVCT) is schdueled to report earning on Oct 05, 2026, Before Open (Confirmed).
    What is Avacta Group PLC (GB:AVCT) earnings time?
    Avacta Group PLC (GB:AVCT) earnings time is at Oct 05, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Avacta Group PLC stock?
          The P/E ratio of Avacta Group plc is N/A.
            What is GB:AVCT EPS forecast?
            Currently, no data Available